Correlation of Interleukin-6 and C-reactive Protein Levels in Plasma with the Stage and Differentiation of Colorectal Cancer: A Cross-sectional Study in East Indonesia

Overview

Journal Ann Med Surg (Lond)

Publisher Wolters Kluwer

Specialty Medical Education

Date 2021 Feb 8

PMID 33552492

Citations 7

Authors

Ferdian Hidayat

Ibrahim Labeda

Samuel Sampetoding

Ilham Jaya Pattelongi

Ronald Erasio Lusikooy

Warsinggih

M Iwan Dani

Mappincara

M Ihwan Kusuma

Julianus Aboyaman Uwuratuw

Erwin Syarifuddin

Muhammad Faruk

Affiliations

Soon will be listed here.

Abstract

Introduction: Tumors most often develop due to inflammatory factors, including inflammatory cells that produce cytokines and cytotoxic mediators that can stimulate malignant transformation. Knowing that interleukin-6 (IL-6) and C-reactive protein (CRP) factor into the development of colorectal cancer (CRC), we aimed to assess IL-6 and CRP's relationship with the stage and differentiation of CRC.

Methods: In a sample of 46 patients with CRC, as confirmed by histopathological examination, plasma levels of IL-6 and CRP were measured from peripheral venous blood samples before surgery and examined using enzyme-linked immunosorbent assay.

Results: Most patients were male (63.0%) and at least 50 years old (73.9%). A positive correlation emerged between stage of CRC and both plasma IL-6 ( 0.396, .003) and CRP ( 0.376, .005) levels, which the Kruskal-Wallis test indicated were highest in stage IV (IL-6: median = 25.80, .019; CRP: median = 34.10, .040). Plasma IL-6 levels (median = 25.80, .019) were higher in well-differentiated CRC, whereas plasma CRP levels (median = 34.10, .040] were higher in poorly differentiated tissue. Linear plotting revealed a linear relationship between plasma IL-6 and plasma CRP levels in patients with CRC.

Conclusion: Because the stage of CRC significantly correlates with plasma IL-6 and CRP levels, IL-6 and CRP can serve as diagnostic factors in assessing the progress and prognosis of CRC.

Citing Articles

Maternal Inflammatory Proteins in Pregnancy and Neurodevelopmental Disorders at Age 10 Years.

Wang T, Mohammadzadeh P, Jepsen J, Thorsen J, Rosenberg J, Koldbaek Lemvigh C JAMA Psychiatry. 2025; .

PMID: 40072459 PMC: 11904801. DOI: 10.1001/jamapsychiatry.2025.0122.

The Significance of C-Reactive Protein Value and Tumor Grading for Malignant Tumors: A Systematic Review.

Siancu P, Oprinca G, Vulcu A, Patran M, Croitoru A, Tanasescu D Diagnostics (Basel). 2024; 14(18).

PMID: 39335753 PMC: 11430861. DOI: 10.3390/diagnostics14182073.

Nivolumab-Induced Cytokine Release Syndrome: A Case Report and Literature Review.

Ntwali F, Gilliaux Q, Honore P Am J Case Rep. 2024; 25:e941835.

PMID: 38625840 PMC: 11034389. DOI: 10.12659/AJCR.941835.

Prognostic Significance of C-Reactive Protein in Lenvatinib-Treated Unresectable Hepatocellular Carcinoma: A Multi-Institutional Study.

Okumura T, Kimura T, Iwadare T, Wakabayashi S, Kobayashi H, Yamashita Y Cancers (Basel). 2023; 15(22).

PMID: 38001602 PMC: 10670047. DOI: 10.3390/cancers15225343.

Changes in Inflammatory Markers in Patients Treated for Buruli Ulcer and Their Ability to Predict Paradoxical Reactions.

Phelippeau M, Marion E, Robbe-Saule M, Ganlanon L, Chauty A, Adeye A J Infect Dis. 2023; 228(11):1630-1639.

PMID: 37221015 PMC: 10681857. DOI: 10.1093/infdis/jiad176.

References

Nagtegaal I, Odze R, Klimstra D, Paradis V, Rugge M, Schirmacher P . The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019; 76(2):182-188. PMC: 7003895. DOI: 10.1111/his.13975. View

Rasic I, Rebic V, Rasic A, Aksamija G, Radovic S . The Association of Simultaneous Increase in Interleukin-6, C Reactive Protein, and Matrix Metalloproteinase-9 Serum Levels with Increasing Stages of Colorectal Cancer. J Oncol. 2018; 2018:2830503. PMC: 6091449. DOI: 10.1155/2018/2830503. View

Holm M, Saraswat M, Joenvaara S, Ristimaki A, Haglund C, Renkonen R . Colorectal cancer patients with different C-reactive protein levels and 5-year survival times can be differentiated with quantitative serum proteomics. PLoS One. 2018; 13(4):e0195354. PMC: 5891022. DOI: 10.1371/journal.pone.0195354. View

Warsinggih , Liliyanto , Prihantono , Ariani G, Faruk M . Colorectal neuroendocrine tumors: A case series. Int J Surg Case Rep. 2020; 72:411-417. PMC: 7306531. DOI: 10.1016/j.ijscr.2020.06.030. View

Laidding S, Josh F, Francisca , Faruk M, Palissei A, Satria B . Combination of platelet-rich plasma and stromal vascular fraction on the level of transforming growth factor-β in rat subjects experiencing deep dermal burn injury. Ann Med Surg (Lond). 2021; 60:737-742. PMC: 7779951. DOI: 10.1016/j.amsu.2020.11.088. View

Agha R, Abdall-Razak A, Crossley E, Dowlut N, Iosifidis C, Mathew G . STROCSS 2019 Guideline: Strengthening the reporting of cohort studies in surgery. Int J Surg. 2019; 72:156-165. DOI: 10.1016/j.ijsu.2019.11.002. View

Thomsen M, Kersten C, Sorbye H, Skovlund E, Glimelius B, Pfeiffer P . Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. Oncotarget. 2016; 7(46):75013-75022. PMC: 5342719. DOI: 10.18632/oncotarget.12601. View

Erlinger T, Platz E, Rifai N, Helzlsouer K . C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004; 291(5):585-90. DOI: 10.1001/jama.291.5.585. View

Amin M, Greene F, Edge S, Compton C, Gershenwald J, Brookland R . The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017; 67(2):93-99. DOI: 10.3322/caac.21388. View

10.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

11.

Zeng J, Tang Z, Liu S, Guo S . Clinicopathological significance of overexpression of interleukin-6 in colorectal cancer. World J Gastroenterol. 2017; 23(10):1780-1786. PMC: 5352918. DOI: 10.3748/wjg.v23.i10.1780. View

12.

Wang S, Sun Y . The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review). Int J Oncol. 2014; 44(4):1032-40. DOI: 10.3892/ijo.2014.2259. View

13.

Nasution R, Islam A, Hatta M, Prihantono , Turchan A, Nasrullah . Role of CAPE in reducing oxidative stress in animal models with traumatic brain injury. Ann Med Surg (Lond). 2020; 57:118-122. PMC: 7390826. DOI: 10.1016/j.amsu.2020.07.036. View

14.

Warsinggih , Irawan B, Labeda I, Lusikooy R, Sampetoding S, Kusuma M . Association of superoxide dismutase enzyme with staging and grade of differentiation colorectal cancer: A cross-sectional study. Ann Med Surg (Lond). 2020; 58:194-199. PMC: 7505864. DOI: 10.1016/j.amsu.2020.08.032. View

15.

Kigawa N, Budhathoki S, Yamaji T, Iwasaki M, Inoue M, Tsugane S . Association of plasma C-reactive protein level with the prevalence of colorectal adenoma: the Colorectal Adenoma Study in Tokyo. Sci Rep. 2017; 7(1):4456. PMC: 5493621. DOI: 10.1038/s41598-017-04780-9. View

16.

Oley M, Oley M, Aling D, Kalangi J, Islam A, Hatta M . Effects of hyperbaric oxygen therapy on the healing of thermal burns and its relationship with ICAM-1: A case-control study. Ann Med Surg (Lond). 2021; 61:104-109. PMC: 7785995. DOI: 10.1016/j.amsu.2020.12.025. View

17.

Siegel R, Miller K, Fedewa S, Ahnen D, Meester R, Barzi A . Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017; 67(3):177-193. DOI: 10.3322/caac.21395. View

18.

Marley A, Nan H . Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet. 2016; 7(3):105-114. PMC: 5069274. View

19.

Waldner M, Foersch S, Neurath M . Interleukin-6--a key regulator of colorectal cancer development. Int J Biol Sci. 2012; 8(9):1248-53. PMC: 3491448. DOI: 10.7150/ijbs.4614. View

20.

Wang X, Dai J, Albanes D, Arndt V, Berndt S, Bezieau S . Mendelian randomization analysis of C-reactive protein on colorectal cancer risk. Int J Epidemiol. 2018; 48(3):767-780. PMC: 6659358. DOI: 10.1093/ije/dyy244. View